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Abstract 
Purpose of review:  
The management of advanced nodal disease in patients treated with 
chemoradiotherapy has been a controversial topic for many years. New data 
has recently been reported, including the results of a multicenter randomized 
trial making this review timely. 
Manuscript (incl Abstract and Keywords)
 2 
Recent findings:  
The PET NECK trial showed that PET CT surveillance is as effective as 
planned neck dissection in terms of overall survival, but results in much fewer 
neck dissections, less complications and is more cost effective. Cost 
effectiveness data from a single centre study demonstrated that strategies 
that include PET CT were more effective than CT-alone guided strategies. 
Summary: There is now level I evidence to support image-guided 
surveillance strategies as the standard of care for advanced nodal disease in 
patients treated with primary chemoradiotherapy. 
 
 
KEY WORDS:  neck dissection, Positron emission tomography, 
chemoradiotherapy 
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Introduction 
The management of advanced nodal (N2-N3) disease in patients with head 
neck cancer treated with primary chemoradiotherapy (CRT) continues to vary 
widely between institutions and countries. Whilst many in the US adopt 
image-guided, response-based strategies, a significant proportion in other 
countries still practice planned neck dissection. For example, up to 48% of 
patients with oropharyngeal cancer in the UK were found to have neck 
dissection as their first treatment in a recent national audit.(1)   In France,  35% 
of head neck clinicians surveyed reported that they commonly or routinely 
performing neck dissection before CRT(2). 
 
These variations in practice are the mainly due to contradicting evidence and 
the lack of randomized comparative studies. This article reviews the most 
recent data in the field: 
 
Literature supporting planned neck dissection 
 
Previous retrospective studies showed that 40% of neck dissections post 
chemoradiotherapy contained persistent disease on histopathological 
examination.(3) There was also level 3 evidence from retrospective studies 
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demonstrating a significant survival advantage in favour of planned neck 
dissection, compared to CRT alone.(4, 5) As a result, traditionally, these 
patients have been treated with a ‘planned’ neck dissection, either before or 
after chemoradiotherapy, despite the risk of significant morbidity and even 
mortality.(6)  
 
 
Literature supporting image-guided surveillance 
As the quality of cross-sectional imaging improved over the past two decades, 
studies consistently reported low rates of recurrence following image-guided 
surveillance. For example, Thariat et al reported rates of recurrence of 4% in 
the 30% of subjects showing complete response on CT scans.(2)  However 
those patients who showed partial response or equivocal complete response 
on CT scanning had high recurrence rates of 37% and 32% if they did not 
have a neck dissection. Such data has stimulated the increasing adoption of 
response-based approaches following CRT. 
 
The efficacy of FDG PET-CT in this indication 
The advent of Positron Emission Tomography (PET), using [18]F-
fluorodeoxyglucose [FDG PET], is a form of functional imaging which 
identifies abnormal metabolic activity of tumour cells and specifically  
increased glucose metabolism in tumour cells. It potentially conferred 
advantages over other cross-sectional imaging modalities in identifying 
residual disease following CRT.  More recently, combined PET-CT scanners 
have been developed.  PET-CT localizes abnormal functional metabolic 
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activity of tumour cells, and also shows structural abnormalities, such as 
nodal enlargement. There have been two notable meta-analyses assessing 
the diagnostic performance of FDG-PET and FDG PET-CT in this indication. 
These have included mainly, single hospital, retrospective and prospective 
studies. The meta-analyses demonstrated high negative predictive values of 
94.5- 96% with positive predictive values of approximately 50% for FDG PET 
and FDG PET-CT scanning following chemoradiotherapy [CRT].(7, 8) FDG PET 
and PET-CT scanning may therefore be able to identify even more patients 
with complete response following chemoradiotherapy, resulting in fewer neck 
dissections.(9)   
 
Till recently, there was no prospective multi-centre, randomised evidence. 
However, the PET NECK study has recently reported(10). The study recruited 
564 patients, randomized into either a planned neck dissection arm or a 
PETCT active surveillance arm. PET CT was non-inferior in terms of overall 
survival (i.e. there was no survival detriment for not having or delaying neck 
dissection) and only 19% of patients had a neck dissection in the PET CT 
arm, with less complications and the same overall  quality of life. The active 
surveillance PET-CT arm was significantly more cost-effective than the 
planned neck dissection arm. 
 
HPV disease and equivocal PET-CT results 
In our PET NECK study, patients with equivocal responses on FDG PET-CT 
scanning received a neck dissection. Our definition of equivocal responses 
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included those patients with residual masses but no FDG uptake or those 
patients with mild FDG uptake regardless of nodal size.   
 
Patients who had demonstrated equivocal complete responses on CT 
scanning after chemoradiotherapy had a high nodal recurrence rate of 37%, 
similar to that of patients who showed partial or no response.(2)   
 
Recent reports suggest HPV+ nodal disease make take longer to reduce in 
size(11),  and therefore may present with equivocal FDG PET-CT scans (in 
particular with enlarged nodes on the CT scan component, but without FDG 
avidity) at the 12 week post CRT assessment. Other recent reports suggest 
that patients who show no FDG uptake had very low recurrence rates, 
especially if they had HPV + disease (93%)(9, 12)  .  Therefore, patients with 
HPV+ disease who show enlarged nodes but no FDG uptake after CRT may 
be considered for close surveillance with serial frequent scans.  Patients with 
FDG uptake should continue to have a neck dissection, especially if they have 
HPV negative or high risk HPV-positive disease. The role of ultrasound 
guided biopsies and diffusion weighted MRI should be evaluated in this group 
of patients.  
 
 
FDG PET-CT versus CT-guided surveillance 
A prospective study by Moeller et al reported that the diagnostic accuracy of 
FDG PET-CT was only better than CT in high-risk patients who have HPV 
negative disease, non-oropharyngeal primaries or who have a smoking or 
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alcohol history. There was no benefit seen in low risk patients who are non-
smokers with HPV+ oropharyngeal primaries(13) . The authors acknowledge 
that the study limited for several reasons. Firstly, it was performed in high-
throughput cancer institution where the proportion of high risk patients and 
radiotherapy non-responders may be greater than in other treatment settings. 
Secondly, FDG PET-CT nodal response was assessed at mean of 8 weeks 
[range 5-12 weeks] following treatment, which may not be the optimal timing 
for FDG PET-CT after RT(7).  And finally, histopathology of post CRT neck 
dissection was used as evidence of persistent disease, which overestimates 
tumour persistence(9, 14).  
 
Indeed, other studies that compared FDG PET-CT to CT have reported much 
higher efficacy of FDG PET-CT compared to CT in HPV+ patients.  Mak et al 
reported that FDG PET/PET-CT scanning at a mean time of 12 weeks [range 
8-16 weeks]  following treatment was  significantly more accurate at predicting   
complete response (90%) compared to contrasted CT assessment (46%), and 
especially for HPV+ patients ( 93% vs 50% )(12).  In one of the largest studies 
to date which specifically considered  FDG PET-CT response in HPV+ 
oropharyngeal cancer,  FDG PET-CT at 12 weeks post CRT  demonstrated 
high NPV for loco-regional failure though with disappointing PPV and 
sensitivity (15).  
 
 Pryor et al demonstrated that surveillance strategies utilising FDG PET-CT 
were more cost effective than CT guided surveillance alone, regardless of the 
HPV status of the patient. Furthermore, that study showed that combined 
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strategies using CT followed by FDG PET-CT in non-responders were only 
slightly more cost effective than FDG PET - CT alone, and were very sensitive 
to changes in circumstances(14).  
 
As yet, independent validation of CT scan-driven response systems or 
comparison with PET-CT –driven systems in multicenter, randomised settings 
have not been published.  Even if further studies shows FDG PET-CT is of 
limited value in HPV+ patients, it should perhaps be noted that in many 
countries, this low risk HPV+ constitutes only a minority of patients, and FDG  
PET-CT would still have a important role in the majority of patients. 
 
Conclusions 
There now appears to be strong, level 1 evidence to support FDG PET-CT - 
guided surveillance for patients with advanced nodal disease treated with 
CRT. There is also a large body of retrospective evidence to support CT 
guided surveillance. However, the available evidence favours FDG PET-CT 
guided policies over CT-only guided regimens on the basis of cost-
effectiveness. 
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